[1]

Husted AS, Trauelsen M, Rudenko O, Hjorth SA, Schwartz TW. 2017. GPCR-mediated signaling of metabolites. Cell Metabolism 25:777−796

doi: 10.1016/j.cmet.2017.03.008
[2]

Qiu S, Cai Y, Yao H, Lin C, Xie Y, et al. 2023. Small molecule metabolites: discovery of biomarkers and therapeutic targets. Signal Transduction and Targeted Therapy 8:132

doi: 10.1038/s41392-023-01399-3
[3]

Palermo A. 2023. Metabolomics- and systems-biology-guided discovery of metabolite lead compounds and druggable targets. Drug Discovery Today 28:103460

doi: 10.1016/j.drudis.2022.103460
[4]

Luzarowski M, Skirycz A. 2019. Emerging strategies for the identification of protein−metabolite interactions. Journal of Experimental Botany 70:4605−4618

doi: 10.1093/jxb/erz228
[5]

Cox MA, Bassi C, Saunders ME, Nechanitzky R, Morgado-Palacin I, et al. 2020. Beyond neurotransmission: acetylcholine in immunity and inflammation. Journal of Internal Medicine 287:120−133

doi: 10.1111/joim.13006
[6]

Kopec AM, Smith CJ, Bilbo SD. 2019. Neuro-immune mechanisms regulating social behavior: dopamine as mediator? Trends in Neurosciences 42:337−348

doi: 10.1016/j.tins.2019.02.005
[7]

Ye D, Xu H, Tang Q, Xia H, Zhang C, et al. 2021. The role of 5-HT metabolism in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1876:188618

doi: 10.1016/j.bbcan.2021.188618
[8]

Myburgh J. 2010. Norepinephrine: more of a neurohormone than a vasopressor. Critical Care 14:196

doi: 10.1186/cc9246
[9]

Piazza I, Kochanowski K, Cappelletti V, Fuhrer T, Noor E, et al. 2018. A map of protein-metabolite interactions reveals principles of chemical communication. Cell 172:358−372.e23

doi: 10.1016/j.cell.2017.12.006
[10]

Li X, Gianoulis TA, Yip KY, Gerstein M, Snyder M. 2010. Extensive in vivo metabolite-protein interactions revealed by large-scale systematic analyses. Cell 143:639−650

doi: 10.1016/j.cell.2010.09.048
[11]

Qin W, Yang F, Wang C. 2020. Chemoproteomic profiling of protein−metabolite interactions. Current Opinion in Chemical Biology 54:28−36

doi: 10.1016/j.cbpa.2019.11.003
[12]

Nicholson JK, Lindon JC. 2008. Metabonomics. Nature 455:1054−1056

doi: 10.1038/4551054a
[13]

Xu H, Zhao H, Ding C, Jiang D, Zhao Z, et al. 2023. Celastrol suppresses colorectal cancer via covalent targeting peroxiredoxin 1. Signal Transduction and Targeted Therapy 8:51

doi: 10.1038/s41392-022-01231-4
[14]

Cheng F, Zhou Y, Li W, Liu G, Tang Y. 2012. Prediction of chemical-protein interactions network with weighted network-based inference method. PLoS One 7:e41064

doi: 10.1371/journal.pone.0041064
[15]

Lounkine E, Keiser MJ, Whitebread S, Mikhailov D, Hamon J, et al. 2012. Large-scale prediction and testing of drug activity on side-effect targets. Nature 486:361−367

doi: 10.1038/nature11159
[16]

Barabási AL, Gulbahce N, Loscalzo J. 2011. Network medicine: a network-based approach to human disease. Nature Reviews Genetics 12:56−68

doi: 10.1038/nrg2918
[17]

Chen B, Butte AJ. 2016. Leveraging big data to transform target selection and drug discovery. Journal of Clinical Pharmacology & Therapeutics 99:285−297

doi: 10.1002/cpt.318
[18]

Zhang Y, Liu C, Liu M, Liu T, Lin H, et al. 2023. Attention is all you need: utilizing attention in AI-enabled drug discovery. Briefings in Bioinformatics 25:bbad467

doi: 10.1093/bib/bbad467
[19]

Wishart DS, Guo A, Oler E, Wang F, Anjum A, et al. 2022. HMDB 5.0: the human metabolome database for 2022. Nucleic Acids Research 50:D622−D631

doi: 10.1093/nar/gkab1062
[20]

Gilson MK, Liu T, Baitaluk M, Nicola G, Hwang L, et al. 2016. BindingDB in 2015: a public database for medicinal chemistry, computational chemistry and systems pharmacology. Nucleic Acids Research 44:D1045−D1053

doi: 10.1093/nar/gkv1072
[21]

Schriml LM, Munro JB, Schor M, Olley D, McCracken C, et al. 2022. The human disease ontology 2022 update. Nucleic Acids Research 50:D1255−D1261

doi: 10.1093/nar/gkab1063
[22]

Gargano MA, Matentzoglu N, Coleman B, Addo-Lartey EB, Anagnostopoulos AV, et al. 2024. The human phenotype ontology in 2024: phenotypes around the world. Nucleic Acids Research 52:D1333−D1346

doi: 10.1093/nar/gkad1005
[23]

Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, et al. 2024. The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Research 52:D1180−D1192

doi: 10.1093/nar/gkad1004
[24]

Yin J, Chen KM, Clark MJ, Hijazi M, Kumari P, et al. 2020. Structure of a D2 dopamine receptor−G-protein complex in a lipid membrane. Nature 584:125−129

doi: 10.1038/s41586-020-2379-5
[25]

Xu P, Huang S, Krumm BE, Zhuang Y, Mao C, et al. 2023. Structural genomics of the human dopamine receptor system. Cell Research 33:604−616

doi: 10.1038/s41422-023-00808-0
[26]

Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, et al. 1997. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753−758

doi: 10.1038/39645
[27]

Toy W, Shen Y, Won H, Green B, Sakr RA, et al. 2013. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nature Genetics 45:1439−1445

doi: 10.1038/ng.2822
[28]

Fortunati N, Catalano MG, Boccuzzi G, Frairia R. 2010. Sex Hormone-Binding Globulin (SHBG), estradiol and breast cancer. Molecular and Cellular Endocrinology 316:86−92

doi: 10.1016/j.mce.2009.09.012
[29]

Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, et al. 2004. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17β-estradiol and phytoestrogens in breast cancer cells. Journal of Biological Chemistry 279:27008−27016

doi: 10.1074/jbc.M403588200
[30]

Wang N, He X, Zhao J, Jiang H, Cheng X, et al. 2022. Structural basis of leukotriene B4 receptor 1 activation. Nature Communications 13:1156

doi: 10.1038/s41467-022-28820-9
[31]

Grishkovskaya I, Avvakumov GV, Sklenar G, Dales D, Hammond GL, et al. 2000. Crystal structure of human sex hormone-binding globulin: steroid transport by a laminin G-like domain. The EMBO Journal 19:504−512

doi: 10.1093/emboj/19.4.504
[32]

Xing C, Zhang J, Zhao H, He B. 2022. Effect of sex hormone-binding globulin on polycystic ovary syndrome: mechanisms, manifestations, genetics, and treatment. International Journal of Women's Health 14:91−105

doi: 10.2147/IJWH.S344542
[33]

Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, et al. 2018. Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism 103:1715−1744

doi: 10.1210/jc.2018-00229
[34]

Terawaki K, Yokomizo T, Nagase T, Toda A, Taniguchi M, et al. 2005. Absence of leukotriene B4 receptor 1 confers resistance to airway hyperresponsiveness and Th2-type immune responses. The Journal of Immunology 175:4217−4225

doi: 10.4049/jimmunol.175.7.4217
[35]

Sumida H, Yanagida K, Kita Y, Abe J, Matsushima K, et al. 2014. Interplay between CXCR2 and BLT1 facilitates neutrophil infiltration and resultant keratinocyte activation in a murine model of imiquimod-induced psoriasis. The Journal of Immunology 192:4361−4369

doi: 10.4049/jimmunol.1302959
[36]

Zhou J, Lai W, Yang W, Pan J, Shen H, et al. 2018. BLT1 in dendritic cells promotes Th1/Th17 differentiation and its deficiency ameliorates TNBS-induced colitis. Cellular & Molecular Immunology 15:1047−1056

doi: 10.1038/s41423-018-0030-2
[37]

Mauvais-Jarvis F, Bhasin S. 2026. Metabolic messengers: testosterone. Nature Metabolism 8:52−61

doi: 10.1038/s42255-025-01431-6
[38]

He R, Chen Y, Cai Q. 2020. The role of the LTB4-BLT1 axis in health and disease. Pharmacological Research 158:104857

doi: 10.1016/j.phrs.2020.104857
[39]

Zheng L, Cao J, Jing L, Kang D, Wang Z, et al. 2026. Convergence of computer-aided drug discovery and artificial intelligence: towards next-generation therapeutics. Pharmaceutical Science Advances 4:100100

doi: 10.1016/j.pscia.2025.100100
[40]

Yang X, Zhang B, Wang S, Lu Y, Chen K, et al. 2023. OTTM: an automated classification tool for translational drug discovery from omics data. Briefings in Bioinformatics 24:bbad301

doi: 10.1093/bib/bbad301
[41]

Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. 2006. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313:1929−1935

doi: 10.1126/science.1132939
[42]

Swinney DC, Anthony J. 2011. How were new medicines discovered? Nature Reviews Drug Discovery 10:507−519

doi: 10.1038/nrd3480
[43]

Eder J, Sedrani R, Wiesmann C. 2014. The discovery of first-in-class drugs: origins and evolution. Nature Reviews Drug Discovery 13:577−587

doi: 10.1038/nrd4336